Introduction
In December 2019, world faced the outbreak of COVID-19 of which the SARS-CoV-2, was known as the causative pathogen. As the virus found its way world spread, in beginning of march 2020 WHO officially declared the disease as a pandemic (1).
Inevitably, massive vaccination became the only way to prevent and control the unleashed pandemic (2). In almost two years 155 vaccine candidates were developed which 23 of them were authorized fallowing different strategies (inactivated, mRNA, viral vector, nanoparticle-based peptide vaccines, etc.). All authorized vaccines have shown promising efficacy; however, the AEs and SAEs remained an unknown challenge (3). The most common AEs were injection site pain or tenderness, fatigue, headache, rash, fever, chill, as well as myalgia, and arthralgia (4). Moreover, thrombosis and thrombocytopenia, myocarditis or pericarditis, inflammatory myositis, and autoimmune diseases were frequently reported SAEs (4, 5). To date few, studies have reported cases of ocular inflammatory AEs after the first or second dose of vaccination, including white dot syndrome, pan uveitis, choroiditis, along with scleritis and scleritis (6, 7).
Herein, we reported a case of 52-year-old woman presented with simple scleritis following third dose of Sinopharm COVID-19 vaccination.